Physician profile
Roxanne Lim
NPI 1154587368
$22,387.11
in general payments reported to CMS, 2019-2025
37 companies · $3,217 in 2025
The $3,217 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,166 · 2020: $5,831 · 2021: $3,964 · 2022: $3,053 · 2023: $2,667 · 2024: $2,490 · 2025: $3,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,630 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $645 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,629.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $645.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $5,612.63 | 2019-2025 | Sucraid, Sucraid |
| Abbvie INC. | $2,998.68 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $2,033.38 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,230.41 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,197.30 | 2019-2025 | Xifaxan, Trulance, Akreos Ao Iol |
| Aimmune Therapeutics, INC. | $1,150.98 | 2024-2025 | Vowst, Zenpep |
| Janssen Biotech, INC. | $1,122.05 | 2020-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $1,119.11 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $1,012.24 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $956.65 | 2022-2025 | Ibsrela |
| Pfizer INC. | $607.82 | 2020-2025 | |
| Allergan, INC. | $572.61 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $445.25 | 2020-2024 | Linzess |
| Redhill Biopharma INC. | $272.66 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Braintree Laboratories, INC. | $244.28 | 2021-2024 | Suflave, Sutab |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.